A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach

<b>Background/Objective:</b> Sacubitril/Valsartan are a combination drug approved for heart failure treatment, known to enhance natriuretic peptide activity and inhibit the renin–angiotensin–aldosterone system (RAAS). While its clinical efficacy is well-established, its broader impact on human metab...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Randh AlAhmari, Hana M. A. Fakhoury, Reem AlMalki, Hatouf H. Sukkarieh, Lina Dahabiyeh, Tawfiq Arafat, Anas M. Abdel Rahman
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	MDPI AG 2025-08-01
Sraith:	Pharmaceuticals
Ábhair:	Sacubitril/Valsartan metabolomics LC-QToF HRMS pyrimidine metabolism pharmacokinetics uridine triphosphate
Rochtain ar líne:	https://www.mdpi.com/1424-8247/18/9/1264
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach

Míreanna comhchosúla